BCRB 2018

19/09/2018

Neo-adjuvant BV in rectal cancer

• Landmark trial: Phase I study results in 6 LARC pts

Bevacizumab 5 mg/kg

Willett Nat Med 2004 Willett CG,J Clin Oncol 2005

Pooled pCR = 22% SELECTION!

19